Futura Medical PLC Futura Medical to Present Data on MED2005 at SMSNA
15 Octubre 2019 - 11:44AM
RNS Non-Regulatory
TIDMFUM
Futura Medical PLC
15 October 2019
Futura Medical to Present Data on MED2005 for the Treatment of
Erectile Dysfunction at the 20(th) Annual Fall Scientific Meeting
of SMSNA and Host Advisory Meeting
15 October 2019
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, today announces that
it will be presenting data on its DermaSys(R) drug delivery
technology and lead product MED2005, a fast-acting, topical,
nitroglycerin (GTN) gel for the treatment of erectile dysfunction
("ED")' at the 20(th) Annual Fall Scientific Meeting of Sexual
Medicine Society of North America (SMSNA), on 24-27 October 2019 at
the Omni Nashville Hotel, Nashville, Tennessee USA. Futura will
also host its third Scientific Advisory Meeting with high profile
US Key Opinion Leaders ("KOLs") in the field of erectile
dysfunction.
Erectile dysfunction disrupts the lives of at least 1 in 5 men
globally(1) , affecting the sexual and emotional health of around
27 million men and their partners in the US alone. There has been
little innovation in ED treatments for over ten years and many
patients continue to suffer dissatisfaction with existing
treatments especially those looking for a fast-acting treatment
that can form part of sexual foreplay or those contraindicated from
using existing therapies.
Tim Holland, Director of Clinical Development at Futura Medical,
will be presenting a poster (#114) entitled "Ultrasound Doppler
Measurements of Penile Blood Flow as a Predictor of Clinical
Efficacy" on Thursday 24 October at 3:20pm CDT. The presentation
will be part of the "Erectile Dysfunction Medical/Surgical
Moderated Posters" session held in the Broadway Ballroom A-B.
In addition, Futura will present cumulative safety data for
MED2005 in an oral presentation (#031) entitled "Establishing the
safety profile in sexual partners of a new topical nitroglycerin
gel for the treatment of erectile dysfunction" on Saturday 26
October at 4:00pm CDT. The presentation will be part of the
"Emerging Treatments for ED and PD" session held in Broadway
Ballroom F.
James Barder, Chief Executive Officer of Futura Medical, said:
"We are very pleased to share these findings on our lead programme
MED2005 with the medical community at this prestigious meeting
ahead of our Phase 3 data readout at the end of the year. MED2005
has the potential to be a highly differentiated therapy, especially
for mild to moderate ED. Shown to be safe and fast-acting (5-10
minutes) with a favourable side effect profile - a key
differentiator to other ED products on the market, which has seen
very little innovation over the past ten years.
"We also look forward to hosting our third Advisory Board Panel
meeting with eminent US Key Opinion Leaders in the field of
erectile dysfunction and discussing this meaningful data and the
on-going development and educational programme for MED2005."
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
About MED2005: Eroxon(R) - Topical treatment for erectile
dysfunction (ED)
MED2005, which uses Futura's DermaSys(R) drug delivery system,
is the development name for its topical glyceryl trinitrate ("GTN")
gel. It has the potential to be a highly differentiated therapy for
the treatment of men with ED, especially mild to moderate ED.
MED2005's rapid onset of action means that it has the potential to
become the world's fastest-acting treatment for ED, with a speed of
onset of around five minutes. Viagra(R) and Cialis(R) which
dominate the existing on-market ED therapies are taken orally and
do not take effect for at least 30 minutes and typically one hour
or more2. Speed of onset and method of administration of MED2005
also help restore spontaneity and intimacy. Importantly, MED2005
may also be appropriate for ED sufferers on nitrates and other
drugs that are contraindicated for use with
phosphodiesterase-5-inhibitors ("PDE5Is") such as Viagra(R) and
Cialis(R) and other existing oral ED treatments.
1. EMEA, Withdrawal assessment report for Viagra, 2008
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGGRWUUPBGQA
(END) Dow Jones Newswires
October 15, 2019 12:44 ET (16:44 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024